Rafa Laboratories Receives Landmark Funding from BARDA
Rafa Laboratories, a leader in medical countermeasures specializing in Chemical, Biological, Radiological, and Nuclear hazards, has announced a monumental contract with the Biomedical Advanced Research and Development Authority, commonly referred to as BARDA. This development contract focuses on the advanced evolution of an intramuscular formulation of tranexamic acid (TXA), which has shown promise as a critical therapy for managing uncontrolled bleeding.
Importance of TXA in Trauma Care
Uncontrolled bleeding is a leading cause of death in trauma scenarios, whether due to accidents, natural disasters, or combat situations. The engagement with BARDA represents a substantial commitment by Rafa to address the urgent need for a straightforward, rapid-response treatment that can be effectively employed in prehospital environments.
Streamlined Administration Process
Currently, TXA is administered intravenously, a process that can be daunting and time-consuming, requiring medical personnel trained to deliver care swiftly during crises. Roy Shay, the Vice President of Biodefense at Rafa Laboratories, emphasized the critical moments that transpire immediately after a hemorrhagic injury, stating that the time before a patient reaches a medical facility is often the most vital.
Improvements Through Autoinjector Technology
To enhance the administration of TXA, Rafa Laboratories is looking into creating an autoinjector, which would allow both medical professionals and lay caregivers to provide this essential life-saving treatment in an emergency context. The intramuscular route presents a user-friendly and quick alternative to the traditional IV approach.
Collaborative Development Strategy
BARDA and Rafa are leveraging a comprehensive strategy for developing this innovative therapy. This approach involves formulation development, manufacturing processes, clinical trials, and a clear pathway for regulatory approval from the U.S. Food and Drug Administration (FDA).
Rafa's Commitment to Medical Innovation
Iddo Leshem, the CEO of Rafa Laboratories, highlighted the company's historical commitment to developing reliable medical solutions for severe, life-threatening conditions. The intramuscular TXA development initiative symbolizes a key enhancement in Rafa's innovative efforts directed at trauma care, showcasing their dedication to saving lives globally.
About Rafa Laboratories
Founded in 1937 and based in Jerusalem, Rafa Laboratories has established itself as a vital contributor to biodefense and emergency medical response. Over the past four decades, the company has supplied various medical products, including autoinjectors, to federal and military entities worldwide. Their impressive portfolio includes FDA-approved products that have been instrumental in emergency healthcare.
Future Prospects
With over 25 years of experience and substantial backing from its controlling shareholder, FIMI Opportunity Funds, Rafa Laboratories is well-positioned to lead advancements in trauma care and emergency medical services. The supporting federal funds from the U.S. Department of Health and Human Services, along with BARDA’s collaboration, drive this commitment further.
Frequently Asked Questions
What is the primary focus of Rafa Laboratories' new funding?
The funding aims to develop an intramuscular formulation of tranexamic acid (TXA) to treat uncontrolled bleeding in emergency situations.
Why is TXA significant in trauma care?
TXA is crucial because it can significantly reduce mortality rates related to hemorrhagic injuries when administered quickly.
How does Rafa Laboratories plan to simplify TXA administration?
By developing an autoinjector, Rafa aims to make TXA administration quick and straightforward for both medical personnel and lay caregivers.
What is the relationship between Rafa and BARDA?
Rafa has collaborated with BARDA on this pivotal contract to expediently develop life-saving treatments for trauma care.
What is Rafa Laboratories' history in the medical field?
Rafa has been a key player in developing medical countermeasures and has supplied products globally for over 40 years.
